Holen Sie sich die Stockscreener-App
72.23
1.43%
1.02
Handel nachbörslich:
72.00
-0.23
-0.32%
Schlusskurs vom Vortag:
$71.21
Offen:
$71.49
24-Stunden-Volumen:
1.65M
Relative Volume:
1.12
Marktkapitalisierung:
$13.78B
Einnahmen:
$2.75B
Nettoeinkommen (Verlust:
$322.29M
KGV:
43.25
EPS:
1.67
Netto-Cashflow:
$300.88M
1W Leistung:
+1.50%
1M Leistung:
+12.98%
6M Leistung:
-14.09%
1J Leistung:
-15.90%
1-Tages-Spanne:
$71.16
$73.51
1-Wochen-Bereich:
$69.89
$73.51
52-Wochen-Spanne:
$60.63
$94.85
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Firmenname
Biomarin Pharmaceutical Inc
Sektor
Branche
Telefon
(415) 506-6700
Adresse
105 DIGITAL DRIVE, NOVATO, CA
Vergleichen Sie BMRN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
72.23 | 13.78B | 2.75B | 322.29M | 300.88M | 1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
488.29 | 125.39B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
707.51 | 77.35B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
594.21 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
244.52 | 31.65B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
247.07 | 26.47B | 3.32B | -860.46M | -1.04B | -8.32 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-24 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-10-30 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-08-20 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | Eingeleitet | Evercore ISI | Outperform |
| 2023-11-15 | Eingeleitet | Wells Fargo | Overweight |
| 2023-10-23 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | Eingeleitet | Raymond James | Mkt Perform |
| 2023-09-18 | Eingeleitet | UBS | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Perform |
| 2023-07-05 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2023-03-21 | Eingeleitet | Bernstein | Underperform |
| 2023-02-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-02-21 | Eingeleitet | Citigroup | Neutral |
| 2023-01-30 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Hold |
| 2022-10-31 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-06-13 | Fortgesetzt | Wedbush | Neutral |
| 2022-04-25 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | Fortgesetzt | Jefferies | Buy |
| 2021-09-09 | Hochstufung | Stifel | Hold → Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-04 | Fortgesetzt | Guggenheim | Buy |
| 2021-03-01 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-08-20 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-08-20 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2020-08-19 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | Herabstufung | Stifel | Buy → Hold |
| 2020-07-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | Bestätigt | Citigroup | Buy |
| 2020-01-28 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-01-27 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-01-24 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-05-23 | Fortgesetzt | Citigroup | Buy |
| 2019-04-09 | Fortgesetzt | Raymond James | Outperform |
| 2019-01-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | Eingeleitet | Wolfe Research | Outperform |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-08-07 | Bestätigt | Stifel | Buy |
| 2018-08-03 | Bestätigt | Stifel | Buy |
Alle ansehen
Biomarin Pharmaceutical Inc Aktie (BMRN) Neueste Nachrichten
BioMarin Pharmaceutical Inc. to Host Earnings Call - ACCESS Newswire
Proficio Capital Partners LLC Takes Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - Defense World
The Top 12 Companies Hiring in Biopharma Now - BioSpace
BioMarin at TD Cowen Conference: Strategic Growth and Innovation - Investing.com
First Week of October 17th Options Trading For BioMarin Pharmaceutical (BMRN) - Nasdaq
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term - Nasdaq
Phenylketonuria Treatment Market Projected To Witness Substantial Growth, 2025-2032: BioMarin Pharmaceutical - EIN News
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Given Average Rating of “Moderate Buy” by Analysts - Defense World
The Strong Earnings Posted By BioMarin Pharmaceutical (NASDAQ:BMRN) Are A Good Indication Of The Strength Of The Business - Simply Wall St
Statutory Profit Doesn't Reflect How Good BioMarin Pharmaceutical's (NASDAQ:BMRN) Earnings Are - Yahoo Finance
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Sold by Sanctuary Advisors LLC - Defense World
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Position Lessened by Handelsbanken Fonder AB - MarketBeat
Los Angeles Capital Management LLC Purchases 28,431 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Fjarde AP Fonden Fourth Swedish National Pension Fund Boosts Stock Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BMRN or CSLLY: Which Is the Better Value Stock Right Now? - Yahoo Finance
Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term - Yahoo Finance Australia
New York State Common Retirement Fund Has $6.16 Million Stock Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Cantor Fitzgerald Has Positive View of BMRN FY2025 Earnings - MarketBeat
Oppenheimer Upgrades BioMarin Pharmaceutical (NASDAQ:BMRN) to "Outperform" - MarketBeat
Investor Network: BioMarin Pharmaceutical Inc. to Host Earnings Call - ACCESS Newswire
Q2 Earnings Estimate for BMRN Issued By Leerink Partnrs - MarketBeat
Research Analysts Set Expectations for BMRN Q1 Earnings - MarketBeat
Global Retirement Partners LLC Increases Stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - Defense World
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CAO Erin Burkhart Sells 1,344 Shares - MarketBeat
Results: BioMarin Pharmaceutical Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - Yahoo Finance
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Sold by Principal Financial Group Inc. - MarketBeat
Principal Securities Inc. Purchases 339 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - Defense World
BioMarin's chief accounting officer sells $91,902 in stock - Investing.com
BioMarin Pharmaceutical Officer Sells Shares - TradingView
Will BioMarin Reveal New Strategic Plans at Upcoming TD Cowen Healthcare Conference? - StockTitan
Oppenheimer Upgrades BioMarin Pharmaceutical (WBAG:BMRN) - Nasdaq
Oppenheimer Upgrades BioMarin Pharmaceutical (LSE:0HNC) - Nasdaq
BioMarin's SWOT analysis: rare disease leader's stock faces growth and competition challenges - Investing.com
Oppenheimer Upgrades BioMarin Pharmaceutical (BMRN) - MSN
BioMarin Expands Board with New Independent Director - MSN
BioMarin stock rating upgraded to Outperform by Oppenheimer - Investing.com Australia
BioMarin expands board, appoints new director By Investing.com - Investing.com Nigeria
BioMarin adds former Horizon CEO to Board of Directors By Investing.com - Investing.com Nigeria
BioMarin expands board, appoints new director - Investing.com India
BioMarin adds former Horizon CEO to Board of Directors - Investing.com India
BioMarin Announces Appointment of Timothy P. Walbert to Board of Directors - PR Newswire
GILD: 3 Pharmaceutical Stocks With Blockbuster Drug Potential - StockNews.com
3 Pharmaceutical Stocks With Blockbuster Drug Potential - TradingView
BIOMARIN PHARMACEUTICAL INC SEC 10-K Report - TradingView
Does BioMarin (BMRN) Have the Potential to Rally 40.54% as Wall Street Analysts Expect? - Yahoo Finance
BioMarin stock rating upgraded to Outperform by Oppenheimer By Investing.com - Investing.com South Africa
Oppenheimer Upgrades BioMarin Pharmaceutical to Outperform From Market Perform, Price Target is $98 - Marketscreener.com
BioMarin Pharmaceutical (NASDAQ:BMRN) Releases FY 2025 Earnings Guidance - MarketBeat
Rhumbline Advisers Purchases 11,025 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin’s Record Growth and 2025 Outlook - TipRanks
BioMarin Pharmaceutical (NASDAQ:BMRN) Shares Gap Up on Strong Earnings - MarketBeat
Finanzdaten der Biomarin Pharmaceutical Inc-Aktie (BMRN)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.67%
0.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):